The complex link between influenza and severe sepsis

Virulence

Volumn 5, Issue 1, 2014, Pages 137-142

  Florescu, Diana F ^a   Kalil, Andre C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Infection; Influenza; Sepsis; Severe sepsis; Viral

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NONSTRUCTURAL PROTEIN 1; RNA POLYMERASE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN;

BACTERIAL INFECTION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PNEUMONIA; REVIEW; SEPSIS; SURVIVAL; VIRUS VIRULENCE;

INFECTION; INFLUENZA; SEPSIS; SEVERE SEPSIS; VIRAL;

COINFECTION; HUMANS; INFLAMMATION; INFLUENZA A VIRUS; INFLUENZA, HUMAN; PNEUMONIA, BACTERIAL; SHOCK, SEPTIC;

EID: 84891652379     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.27103     Document Type: Review

References (95)

1. Florescu DF, Kalil AC. Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unit. Infect Disord Drug Targets 2011; 11:354-64. PMID:21679146; http://dx.doi.org/10.2174/187152611796504773
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50. PMID:12519925; http://dx.doi.org/10.1056/NEJMra021333
3. Brown MA, Jones WK. NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 2004; 9:1201-17. PMID:14977537; http://dx.doi.org/10.2741/1304
4. Russell JA. Management of sepsis. N Engl J Med 2006; 355:1699-713. PMID:17050894; http://dx.doi.org/10.1056/NEJMra043632
5. García-Sastre A. Induction and evasion of type I interferon responses by influenza viruses. Virus Res 2011; 162:12-8. PMID:22027189; http://dx.doi.org/10.1016/j.virusres.2011.10.017
6. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Rosen H. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146:980-91. PMID:21925319; http://dx.doi.org/10.1016/j.cell.2011.08.015
7. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methods. Antiviral Res 2012; 93:2-15. PMID:22068147; http://dx.doi.org/10.1016/j.antiviral.2011.10.019
8. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M, Kido H. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010; 202:991-1001. PMID:20731583; http://dx.doi.org/10.1086/656044
9. Armstrong SM, Mubareka S, Lee WL. The lung microvascular endothelium as a therapeutic target in severe influenza. Antiviral Res 2013; 99:113-8. PMID:23685311; http://dx.doi.org/10.1016/j.antiviral.2013.05.003
10. Guarner J, Falcón-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 2009; 40:655-61. PMID:20304252; http://dx.doi.org/10.1016/j.arcmed.2009.10.001
11. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, et al.; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-9. PMID:19564631; http://dx.doi.org/10.1056/NEJMoa0904252
12. Ng WF, To KF. Pathology of human H5N1 infection: new findings. Lancet 2007; 370:1106-8. PMID:17905148; http://dx.doi.org/10.1016/S0140-6736(07)61490-1
13. Uiprasertkul M, Kitphati R, Puthavathana P, Kriwong R, Kongchanagul A, Ungchusak K, Angkasekwinai S, Chokephaibulkit K, Srisook K, Vanprapar N, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 2007; 13:708-12. PMID:17553248; http://dx.doi.org/10.3201/eid1305.060572
14. Guarner J, Paddock CD, Shieh WJ, Packard MM, Patel M, Montague JL, Uyeki TM, Bhat N, Balish A, Lindstrom S, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season. Clin Infect Dis 2006; 43:132-40. PMID:16779738; http://dx.doi.org/10.1086/505122
15. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435-6. PMID:16554799; http://dx.doi.org/10.1038/440435a
16. Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors. Curr Opin Immunol 2011; 23:481-6. PMID:21840185; http://dx.doi.org/10.1016/j.coi.2011.07.016
17. Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS, Chai W, Daniels R, Gregory V, Uhlendorff J, Kiso M, et al. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 2010; 84:12069-74. PMID:20826688; http://dx.doi.org/10.1128/JVI.01639-10
18. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2006; 444:378-82. PMID:17108965; http://dx.doi.org/10.1038/nature05264
19. Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC. Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J Virol 2010; 84:7569-80. PMID:20504924; http://dx.doi.org/10.1128/JVI.00291-10
20. Ghosh S, Gregory D, Smith A, Kobzik L. MARCO regulates early inflammatory responses against influenza: a useful macrophage function with adverse outcome. Am J Respir Cell Mol Biol 2011; 45:1036-44. PMID:21562316; http://dx.doi.org/10.1165/rcmb.2010-0349OC
21. Marsolais D, Hahm B, Walsh KB, Edelmann KH, McGavern D, Hatta Y, Kawaoka Y, Rosen H, Oldstone MB. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A 2009; 106:1560-5. PMID:19164548; http://dx.doi.org/10.1073/pnas.0812689106
22. Walsh KB, Marsolais D, Welch MJ, Rosen H, Oldstone MB. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 2010; 397:260-9. PMID:19962171; http://dx.doi.org/10.1016/j.virol.2009.08.043
23. Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, Staudt LM, Rosenwald A, Behrends U, Bornkamm GW, et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004; 85:2347-56. PMID:15269376; http://dx.doi.org/10.1099/vir.0.79958-0
24. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78:539-52. PMID:19413999; http://dx.doi.org/10.1016/j.bcp.2009.04.029
25. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133:235-49. PMID:18423196; http://dx.doi.org/10.1016/j.cell.2008.02.043
26. Ricciardolo FL, Di Stefano A, Sabatini F, Folkerts G. Reactive nitrogen species in the respiratory tract. Eur J Pharmacol 2006; 533:240-52. PMID:16464450; http://dx.doi.org/10.1016/j.ejphar.2005.12.057
27. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7. PMID:12480361; http://dx.doi.org/10.1016/S0140-6736(02)11772-7
28. Perrone LA, Belser JA, Wadford DA, Katz JM, Tumpey TM. Inducible nitric oxide contributes to viral pathogenesis following highly pathogenic influenza virus infection in mice. J Infect Dis 2013; 207:1576-84. PMID:23420903; http://dx.doi.org/10.1093/infdis/jit062
29. Gavard J, Gutkind JS. VEGF controls endothelialcell permeability by promoting the beta-arrestindependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8:1223-34. PMID:17060906; http://dx.doi.org/10.1038/ncb1486
30. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121:2115-22. PMID:18565824; http://dx.doi.org/10.1242/jcs.017897
31. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA, Wythe JD, Suh W, Larrieu-Lahargue F, Mukouyama YS, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008; 14:448-53. PMID:18345009; http://dx.doi.org/10.1038/nm1742
32. Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol 2009; 11:1325-31. PMID:19855388; http://dx.doi.org/10.1038/ncb1976
33. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010; 2:23ra19. PMID:20375003; http://dx.doi.org/10.1126/scitranslmed.3000678
34. Friesenhagen J, Boergeling Y, Hrincius E, Ludwig S, Roth J, Viemann D. Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. J Leukoc Biol 2012; 92:11-20. PMID:22442495; http://dx.doi.org/10.1189/jlb.0911479
35. Berdal JE, Mollnes TE, Wæhre T, Olstad OK, Halvorsen B, Ueland T, Laake JH, Furuseth MT, Maagaard A, Kjekshus H, et al. Excessive innate immune response and mutant D222G/N in severe A (H1N1) pandemic influenza. J Infect 2011; 63:308-16. PMID:21781987; http://dx.doi.org/10.1016/j. jinf.2011.07.004
36. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le Mt, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 2011; 92:1428-34. PMID:21367984; http://dx.doi.org/10.1099/vir.0.030346-0
37. Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, Brezoszki ES, Maxim M, Ciuce C, Mlesnite M, Gavrus RL, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care 2010; 14:R203. PMID:21062445; http://dx.doi.org/10.1186/cc9324
38. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, Vogel SN. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol 2010; 3:29-39. PMID:19865078; http://dx.doi.org/10.1038/mi.2009.120
39. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497:498-502. PMID:23636320; http://dx.doi.org/10.1038/nature12118
40. Esposito S, Molteni CG, Giliani S, Mazza C, Scala A, Tagliaferri L, Pelucchi C, Fossali E, Plebani A, Principi N. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/ H1N1/2009 influenza in otherwise healthy children. Virol J 2012; 9:270. PMID:23151015; http://dx.doi.org/10.1186/1743-422X-9-270
41. Hidaka F, Matsuo S, Muta T, Takeshige K, Mizukami T, Nunoi H. A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy. Clin Immunol 2006; 119:188-94. PMID:16517210; http://dx.doi.org/10.1016/j.clim.2006.01.005
42. Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N, Viswan NA, Al-Ashgar H, Al-Humaidan H, Al-Suwayeh R, et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 2012; 84:1353-9. PMID:22825813; http://dx.doi.org/10.1002/jmv.23271
43. Kido H, Chen Y, Yamada H, Okumura Y. [Host cellular proteases trigger the infectivity of the influenza virus in the airway and brain]. Nihon Yakurigaku Zasshi 2003; 122:45-53. PMID:12843572; http://dx.doi.org/10.1254/fpj.122.45
44. Le TQ, Kawachi M, Yamada H, Shiota M, Okumura Y, Kido H. Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain. Biol Chem 2006; 387:467-75. PMID:16606346
45. Duncan ME, Richardson JP, Murray GI, Melvin WT, Fothergill JE. Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem 1998; 258:37-43. PMID:9851689; http://dx.doi.org/10.1046/j.1432-1327.1998.2580037.x
46. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006; 203:1007-19. PMID:16585265; http://dx.doi.org/10.1084/jem.20051342
47. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82. PMID:16847087; http://dx.doi.org/10.1128/CMR.00058-05
48. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012; 205:458-65. PMID:22158564; http://dx.doi.org/10.1093/infdis/jir749
49. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6:303-12. PMID:16631551; http://dx.doi.org/10.1016/S1473-3099(06)70466-2
50. Centers for Disease Control and Prevention (CDC). Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1341-4. PMID:20010508
51. Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, Moore MR; Active Bacterial Core Surveillance Team. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50:175-83. PMID:20014948; http://dx.doi.org/10.1086/649208
52. Grabowska K, Högberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 2006; 6:58. PMID:16549029; http://dx.doi.org/10.1186/1471-2334-6-58
53. Hers JF, Masurel N, Mulder J. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet 1958; 2:1141-3. PMID:13612141; http://dx.doi.org/10.1016/S0140-6736(58)92404-8
54. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134:1040-4. PMID:3777666
55. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341-50. PMID:12134230; http://dx.doi.org/10.1086/341462
56. Hament JM, Kimpen JL, Fleer A, Wolfs TF. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999; 26:189-95. PMID:10575129; http://dx.doi.org/10.1111/j.1574-695X.1999.tb01389.x
57. Tong HH, McIver MA, Fisher LM, DeMaria TF. Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis mediaassociated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium. Microb Pathog 1999; 26:111-9. PMID:10090858; http://dx.doi.org/10.1006/mpat.1998.0257
58. Kleinerman ES, Daniels CA, Polisson RP, Snyderman R. Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice. Am J Pathol 1976; 85:373-82. PMID:11695
59. Abramson JS, Giebink GS, Quie PG. Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect Immun 1982; 36:289-96. PMID:7076299
60. Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990; 58:2809-14. PMID:2143751
61. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol 1994; 68:3667-73. PMID:8189504
62. Hartshorn KL, Liou LS, White MR, Kazhdan MM, Tauber JL, Tauber AI. Neutrophil deactivation by influenza A virus. Role of hemagglutinin binding to specific sialic acid-bearing cellular proteins. J Immunol 1995; 154:3952-60. PMID:7706733
63. Colamussi ML, White MR, Crouch E, Hartshorn KL. Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 1999; 93:2395-403. PMID:10090951
64. Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, Shay DK, Nateri J, Greathouse K, Sullivan R, et al.; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network PICFlu Study Investigators. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 2013; 41:224-36. PMID:23222256; http://dx.doi.org/10.1097/CCM.0b013e318267633c
65. Passariello C, Nencioni L, Sgarbanti R, Ranieri D, Torrisi MR, Ripa S, Garaci E, Palamara AT. Viral hemagglutinin is involved in promoting the internalisation of Staphylococcus aureus into human pneumocytes during influenza A H1N1 virus infection. Int J Med Microbiol 2011; 301:97-104. PMID:20940105; http://dx.doi.org/10.1016/j.ijmm.2010.06.008
66. Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Influenzaassociated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus--United States, 2009. Clin Infect Dis 2012; 54:1221-9. PMID:22437239; http://dx.doi.org/10.1093/cid/cis197
67. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, Paley MA, Antenus M, Williams KL, Erikson J, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012; 37:158-70. PMID:22705104; http://dx.doi.org/10.1016/j.immuni.2012.04.011
68. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86. PMID:12517228; http://dx.doi.org/10.1001/jama.289.2.179
69. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenzaassociated hospitalizations in the United States. JAMA 2004; 292:1333-40. PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333
70. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12:687-95. PMID:22738893; http://dx.doi.org/10.1016/S1473-3099(12)70121-4
71. Chu CM. The etiology and epidemiology of influenza: an analysis of the 1957 epidemic. J Hyg Epidemiol Microbiol Immunol 1958; 2:1-8. PMID:13598889
72. Patterson KD. Pandemic Influenza, 1700-1900: A Study in Historical Epidemiology. Totowa, N.J.:Rowan & Littlefield, 1986.
73. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53-60. PMID:9652423; http://dx.doi.org/10.1086/515616
74. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am 2004; 18:141-55. PMID:15081510; http://dx.doi.org/10.1016/S0891-5520(03)00095-3
75. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, et al.; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-9. PMID:19822627; http://dx.doi.org/10.1001/jama.2009.1496
76. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007; 195:1018-28. PMID:17330793; http://dx.doi.org/10.1086/511989
77. Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol 2000; 10:119-33. PMID:10713598; http://dx.doi.org/10.1002/(SICI)1099-1654(200003/04)10:2119::AIDRMV2723.0.CO;2-O
78. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, Poblano-Morales M, Baltazar-Torres JA, Bautista E, Martinez A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-7. PMID:19822626; http://dx.doi.org/10.1001/jama.2009.1536
79. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, et al.; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44. PMID:19815859; http://dx.doi.org/10.1056/NEJMoa0906695
80. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, et al.; California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896-902. PMID:19887665; http://dx.doi.org/10.1001/jama.2009.1583
81. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, et al.; Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19. PMID:20445182; http://dx.doi.org/10.1056/NEJMra1000449
82. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739-47. PMID:21606532; http://dx.doi.org/10.1093/infdis/jir187
83. Farias JA, Fernández A, Monteverde E, Vidal N, Arias P, Montes MJ, Rodríguez G, Allasia M, Ratto ME, Jaén R, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015-22. PMID:20237757; http://dx.doi.org/10.1007/s00134-010-1853-1
84. Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O, Lauria FN, Ferraro F, Antonini M, Ippolito G, et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 2010; 202:681-9. PMID:20670171; http://dx.doi.org/10.1086/655469
85. Lister P, Reynolds F, Parslow R, Chan A, Cooper M, Plunkett A, Riphagen S, Peters M. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009; 374:605-7. PMID:19700000; http://dx.doi.org/10.1016/S0140-6736(09)61512-9
86. Caprotta G, González Crotti P, Primucci Y, Alesio H, Esen A. [Influenza A H1N1 respiratory infection in an intensive care unit in Argentina]. An Pediatr (Barc) 2010; 72:62-6. PMID:19836321; http://dx.doi.org/10.1016/j.anpedi.2009.09.002
87. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2013; 37:333-40. PMID:22546772; http://dx.doi.org/10.1038/ijo.2012.62
88. López-Aldeguer J, Iribarren JA, Valencia E, Barquilla E, Knobel H, Santos J, Lozano F; GESIDA 6409 Study Group. Outcomes in HIV-infected patients admitted due to pandemic influenza. Enferm Infecc Microbiol Clin 2012; 30:608-12. PMID:22459686; http://dx.doi.org/10.1016/j.eimc.2012.02.007
89. Morgan CI, Hobson MJ, Seger B, Rice MA, Staat MA, Wheeler DS. 2009 pandemic influenza A (H1N1) in critically ill children in Cincinnati, Ohio. Pediatr Crit Care Med 2012; 13:e140-4. PMID:21760562; http://dx.doi.org/10.1097/PCC.0b013e318228845f
90. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, Low DE; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75. PMID:18190317; http://dx.doi.org/10.1086/523584
91. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 2009; 339:b3172. PMID:19666987; http://dx.doi.org/10.1136/bmj.b3172
92. Lee N, Wong CK, Chan PK, Chan MC, Wong RY, Lun SW, Ngai KL, Lui GC, Wong BC, Lee SK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 2011; 6:e26050. PMID:22022504; http://dx.doi.org/10.1371/journal.pone.0026050
93. Han K, Ma H, An X, Su Y, Chen J, Lian Z, Zhao J, Zhu BP, Fontaine RE, Feng Z, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53:326-33. PMID:21810744; http://dx.doi.org/10.1093/cid/cir398
94. Brun-Buisson C, Richard JC, Mercat A, Thiébaut AC, Brochard L; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-6. PMID:21471082; http://dx.doi.org/10.1164/rccm.201101-0135OC
95. Fedson DS, Opal SM. Research into transmissibility of influenza A H5N1: a practical response to the controversy. Lancet Infect Dis 2012; 12:364-5. PMID:22541628; http://dx.doi.org/10.1016/S1473-3099(12)70079-8